FAQ: NSCLC Immunotherapy
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer

Released: November 23, 2021

Expiration: November 22, 2022

Julie Brahmer
Julie Brahmer, MD
Jarushka Naidoo
Jarushka Naidoo, MB BCH BAO, MHS

Activity

Progress
1
Course Completed

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:

  • Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens
  • Second-line therapeutic options after disease progression on an immunotherapy-based regimen
  • Immunotherapy in patients with advanced NSCLC and brain metastases
  • Distinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsy
  • Future directions in immunotherapy for NSCLC, including the role of the gut microbiome in response